Dunlop's 20% w/v PMD Solution for Injection

Summary of Product characteristics

                                Revised: July 2010
ATCVet code amended
1
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Dunlop’s 20% w/v PMD Solution for Injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Contains Calcium Gluconate
16.6% w/v
Magnesium Hypophosphite Hexahydrate
5% w/v
Glucose Monohydrate
22.0% w/v
Each 400 ml contains:
5.92 g calcium (provided by calcium gluconate and calcium
borogluconate)
1.84 g magnesium (provided by magnesium hypophosphite
hexahydrate)
80 g glucose provided by glucose monohydrate.
Also contains 3.40% w/v boric aid.
EXCIPIENTS:
Chlorocresol
0.1% w/v
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection
A clear, pale yellow aqueous solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Sheep
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of hypocalcaemia complicated by deficiency of
magnesium with accompanying hypoglycaemia. In the treatment of
pregnancy toxaemia and other metabolic imbalances in periparturient
sheep
Revised: July 2010
ATCVet code amended
2
4.3
CONTRAINDICATIONS
Not to be administered by intravenous or intramuscular routes
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
No special warning.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
The solution should be warmed to body temperature before
administration.
ii.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Care should be taken to avoid accidental self-injection.
If accidental self-injection occurs, seek medical advice. Wash
hands after use.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Can be safely administered to pregnant and lactating animals
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known
4.9
AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
The solution should be warmed to body temperature before
administration by subcutaneous injection only. Observe 
                                
                                Read the complete document